Loading
A phase 1 trial of tulmimetostat in mycosis fungoides and Sezary syndrome, run by Washington University School of Medicine, active but no longer recruiting.
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome is a phase 1 interventional study registered as NCT05944562 by Washington University School of Medicine, with Novartis, The Foundation for Barnes-Jewish Hospital, Swim Across America, Daniel E. Corbin Jr. Lymphoma Fund as collaborators; 24 participants are planned, it started on 2024-01-09; the registry gives 2027-02-28 as its primary completion date. Interventions recorded: Tulmimetostat. Conditions listed: Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome. No results are recorded here; the registry entry is the source.
Shares Tulmimetostat, Novartis and the tag pipeline.
Shares Tulmimetostat, Novartis and the tag pipeline.
Shares Tulmimetostat and the tag pipeline.
Shares Mycosis fungoides, Sezary syndrome and the tag pipeline.
Shares Mycosis fungoides, Sezary syndrome and the tag pipeline.
Shares Mycosis fungoides and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Novartis and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/